Table 2.
Baseline characteristics of whole study sample and bivariate analysis according to symptomatic intracranial hemorrhage.
| No sICH (n = 1,374) | sICH (n = 81) | p-value | |
|---|---|---|---|
| Age (year, mean ± SD) | 72.3 ± 12.9 | 73.4 ± 11.1 | 0.78 |
| Sex [women; n (%)] | 631 (46) | 33 (42) | 0.48 |
| Hypertension [n (%)] | 874 (64) | 53 (65) | 0.81 |
| Diabetes mellitus [n (%)] | 266 (20) | 19 (24) | 0.38 |
| Dyslipidemia [n (%)] | 668 (49) | 37 (46) | 0.64 |
| Atrial fibrillation [n (%)] | 376 (28) | 26 (33) | 0.47 |
| History of coronary disease [n (%)] | 187 (14) | 10 (12) | 0.86 |
| Previous Stroke [n (%)] | 172 (13) | 16 (20) | 0.08 |
| Smoking (current or past) [n (%)] | 437 (33) | 26 (32) | 0.49 |
| Prior mRS 0–1 [n (%)] | 1218 (89) | 64 (79) | 0.01 |
| OAC [n (%)] | 254 (19) | 20 (25) | 0.18 |
| Treatment with VKA | 174 (13) | 19 (24) | 0.01 |
| Treatment with DOACs | 80 (6) | 1 (1.2) | 0.08 |
| Antiplatelet [any, n (%)] | 329 (24) | 14 (17) | 0.5 |
| Acetylsalicylic acid [n (%)] | 264 (19) | 13 (16) | 0.56 |
| Clopidogrel [n (%)] | 36 (3) | 1 (1) | 0.7 |
| Double antiplatelet therapy [n (%)] | 18 (1) | 0 | 0.61 |
| Baseline NIHSS [median, (IQR)] | 16 (10–20) | 18 (13–21) | 0.02 |
| Baseline ASPECTS [median, (IQR)] | 9 (8–10) | 8 (9–7) | <0.001 |
| MCA-M1 occlusion [n (%)] | 755 (56) | 37 (46) | 0.04 |
| Tandem occlusion [n (%)] | 232 (17) | 18 (22) | 0.22 |
| TOAST [cardioembolic origin; n (%)] | 649 (50) | 33 (45) | 0.81 |
| Known time of symptom onset (%) | 912 (66) | 52 (64) | 0.71 |
| Time intervals [median (IQR) min] | |||
| Onset-to-door time | 110 (60–224) | 164 (90–265) | <0.001 |
| Onset-to-arterial puncture | 214 (160–315) | 278 (217–356) | <0.001 |
NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of Org 10172 in acute stroke registry; ASPECTS, Alberta Stroke Program Early CT Score; MCA, middle cerebral artery; IQR, interquartile range; mRS, modified Rankin Scale; OAC, oral anticoagulation; DOACs, direct oral anticoagulants; VKA, vitamin K antagonist.